Hi tschussmann, I don't think that Anavex can do that. When precision medicine is referred to, it is in the context of testing and measuring and not designing (at least in this case.) Anavex doesn't really know how 2-73 works or why it works incredibly well for 1/3 of patients and not for 2/3s of the rest of them. I once had a call with IR and asked why they didn't run bigger trials and they said "We didn't know it would work." What they do know, and what they mean by precision medicine, is that the drug works consistently well for specific genetic profiles. Because they don't know why, I don't think they can design therapies for the other subgroups - at least not now and with any degree of certainty.
Market Data 
Markets 
